Should I Buy ITRM? ITRM 2026 Analysis

Should You Buy Iterum Therapeutics PLC (ITRM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.300

1 Day change

5.96%

52 Week Range

1.600

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: the chart structure is still bearish (SMA_200 > SMA_20 > SMA_5) and price is below the pivot (0.334).
With no Intellectia buy signals today and no near-term news catalysts, upside looks limited and the risk of a push toward support (0.292) remains.
I would only turn constructive if price reclaims the pivot (0.334) and then holds above 0.375 (R1); until then, it’s a pass for a fresh entry.

Technical Analysis

Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend across long-, mid-, and short-term horizons.
Momentum: MACD histogram is slightly positive (0.00167) but positively contracting, suggesting bullish momentum is fading rather than expanding.
RSI(6): 40.075 (neutral-weak), not oversold—so there isn’t a strong “snap-back” oversold setup.
Key levels: Premarket ~0.3091 is below Pivot 0.334.
- Support: 0.292 (S1), then 0.267 (S2)
- Resistance: 0.334 (Pivot), 0.375 (R1), 0.400 (R2)
Pattern-based projection (similar candlesticks): only modest expected upside (next month +4.51%) with 50% probability—doesn’t outweigh the bearish structure.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

and reclaims pivot (0.334), a short-term mean reversion bounce toward 0.375 becomes more plausible.

Neutral/Negative Catalysts

keeps trend pressure to the downside.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0.39M, essentially flat YoY (up 0.00%)—no meaningful growth trend.
Net income: -8.979M, improved YoY by 47.34% (loss narrowing), but still materially negative.
EPS: -0.20, worse YoY (down -33.33%), indicating per-share profitability deteriorated despite the net loss improvement.
Gross margin: 5.38 (flat YoY), still very low, suggesting limited operating leverage at current scale.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating / price target change data was provided, so there’s no clear read on recent Wall Street upgrades/downgrades.
Practical takeaway: without visible analyst support/trend plus no catalysts, sentiment tailwinds appear absent, reinforcing a non-buy stance right now.

2 Analyst Rating

Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 5.5 USD with a low forecast of 2 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.285

Low

Averages

5.5

High

Current: 0.285

Low

Averages

5.5

High

H.C. Wainwright

initiated

AI Analysis

2025-05-08

Reason